

This is the author's manuscript



AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Use of probiotics in the Helicobacter pylori eradication in Italy: data from the Italian Registry on Helicobacter pylori treatment

| Original Citation: | |
|--|----------------------------|
| | |
| | |
| A 4 1 112 | |
| Availability: | |
| This version is available http://hdl.handle.net/2318/1713456 | since 2019-10-13T11:07:23Z |
| | |
| | |
| | |
| | |
| Terms of use: | |
| Open Access | |
| Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law. | |
| | |

(Article begins on next page)

P1.25

Use of probiotics in the *Helicobacter pylori* eradication in Italy: data from the Italian Registry on *Helicobacter pylori* treatment

R. Zagari¹, A. Romiti¹, G. Fiorini¹, I. Saracino¹, D. Ribaldone², A. Panarese³, F. Lella⁴, F. Gigliotti⁵, A. Gasbarrini⁶, O. Paoluziˀ, G. Del Vecchio Blancoˀ, M. Romano⁶, B. Annibale⁶, L. Broglia¹⁰, R. Catanzaro¹¹, C. Marfinati Hervoso¹², F. Luzza¹³, G. Nardone¹⁴, R. Conigliaro¹⁵, R. Cannizzaro¹⁶, M. Pavoni¹, B. Vaira¹, R. Pellicano², M. Ferrara⁵, F. Bazzoli¹

¹Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; ¹⁰Unit of Gastroenterology, SS Trinità Hospital, Borgomanero (Novara), Italy; ¹¹Gastroenterology and Hepatology Service, Internal Medicine Unit, University Hospital "G. Rodolico", Catania, Italy; ¹²Division of Gastroenterology, "A. Manzoni" Hospital, Lecco, Italy; ¹³Department of Health Sciences, University Magna Græcia, Catanzaro, Italy; ¹⁴Department of Clinical Medicine and Surgery, Hepato-Gastroenterology Unit, University of Naples "Federico II", Naples, Italy; ¹⁵Gastroenterology and Digestive Endoscopy Department, Sant'Agostino Estense Hospital, Baggiovara (Modena), Italy; ¹⁶Department of Gastroenterology, Istituto Nazionale Tumori IRCCS, Aviano (Pordenone), Italy; ²General and Specialistic Medical Department, Division of Gastroenterology, AOU Città della Salute e della Scienza, Turin, Italy; ³Department of Gastroenterology and Digestive Endoscopy, IRCCS "Saverio De Bellis", Castellana Grotte (Bari), Italy; 4Gastroenterology Unit, Policlinico San Pietro, Bergamo, Italy; 5Gastroenterology and Endoscopic Unit, San Giovanni Calibita-Fatebenefratelli Hospital, Rome, Italy; Gastroenterology Area, Fondazione Policlinico Universitario A Gemelli, Università Cattolica, Rome, Italy; ⁷Department of System Medicine, University of Tor Vergata, Rome, Italy; Department of Precision Medicine "F. Magrassi", University of Campania, Naples, Italy; 9Medical-Surgical Department of Clinical Sciences and Translational Medicine, University Sapienza, Rome, Italy

Background: Probiotics may have beneficial effect in reducing adverse events in patients treated for *Helicobacter (H.) pylori* infection; however, data on their use in this setting are scarce.

Aim: To investigate the use of probiotic supplementation in the treatment of *H. pylori* infection in clinical practice in Italy.

Methods: The "Italian Registry on *H. pylori* treatment" is an online database prospectively registering adult patients prescribed with a treatment for *H. pylori* infection by gastroenterologists in Italy. Data were collected in 17 Centers from June 2017 to May 2019 using the web application REDCap (Research Electronic Data Capture).

Results: A total of 1803 patients [1140 (63.5%) females, mean age (SD): 55.4 years (15.1)] were included in the Registry in the study period. Of these, 1699 received one treatment regimen, 101 two regimens and 3 three regimens, with a total of 1910 cases. Probiotics were prescribed in 49.9% (n. 953) of cases: 100% (61/61) with rifabutin triple therapy, 86.4% (472/546) with sequential therapy, 54.2% (77/142) with levofloxacin triple therapy, 46.3% (38/82) with concomitant therapy, 33% (211/641) with bismuth quadruple therapy (Pylera®), 24.1% (90/374) with clarithromycin triple therapy and 21.1% (4/19) with other regimens. The most frequently prescribed probiotic was a combination of *Lactobacillus rhamnosus* and *Bifidobacterium breve* (586, 61.5%), followed by *Lactobacillus casei DG* (118, 12.4%), *Lactobacillus rhamnosus* (85, 8.9%), *Saccaromyces boulardii* (74, 7.8%) and others probiotics (90, 9.4%). Conclusions

Probiotic supplementation is used in half of patients treated for *H. pylori* eradication in Italy. *Lactobacillus* and *Bifidobacterium* are the probiotics most commonly prescribed.

R. Zagari: D. Speakers Bureau/Honoraria (speakers bureau, symposia, and expert witness); Modest; Takeda, Italy. A. Romiti: None. G. Fiorini: None. I. Saracino: None. D. Ribaldone: None. A. Panarese: None. F. Lella: None. F. Gigliotti: None. A. Gasbarrini: None. G. Del Vecchio Blanco: None. M. Romano: None. B. Annibale: None. L. Broglia: None. R. Catanzaro: None. C. Marfinati Hervoso: None. F. Luzza: None. G. Nardone: None. R. Conigliaro: None. R. Cannizzaro: None. M. Pavoni: None. B. Vaira: None. R. Pellicano: None. M. Ferrara: None. F. Bazzoli: None. O. Paoluzi: None.